CL2013002068A1 - Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma. - Google Patents

Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma.

Info

Publication number
CL2013002068A1
CL2013002068A1 CL2013002068A CL2013002068A CL2013002068A1 CL 2013002068 A1 CL2013002068 A1 CL 2013002068A1 CL 2013002068 A CL2013002068 A CL 2013002068A CL 2013002068 A CL2013002068 A CL 2013002068A CL 2013002068 A1 CL2013002068 A1 CL 2013002068A1
Authority
CL
Chile
Prior art keywords
inactivated
genes
mouse
hybridoma
viable
Prior art date
Application number
CL2013002068A
Other languages
English (en)
Inventor
Jacinthe Gingras
Stefan L Mcdonough
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2013002068A1 publication Critical patent/CL2013002068A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/061—Sperm cells, spermatogonia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2013002068A 2011-01-18 2013-07-18 Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma. CL2013002068A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161433910P 2011-01-18 2011-01-18
US201161557877P 2011-11-09 2011-11-09

Publications (1)

Publication Number Publication Date
CL2013002068A1 true CL2013002068A1 (es) 2014-05-16

Family

ID=45561108

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002068A CL2013002068A1 (es) 2011-01-18 2013-07-18 Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma.

Country Status (13)

Country Link
US (1) US20120185956A1 (es)
EP (1) EP2665822A1 (es)
JP (1) JP2014507136A (es)
KR (1) KR20140009311A (es)
CN (1) CN103492575A (es)
AU (1) AU2012207366A1 (es)
CA (1) CA2823707A1 (es)
CL (1) CL2013002068A1 (es)
EA (1) EA201370161A1 (es)
MX (1) MX2013008282A (es)
SG (1) SG191993A1 (es)
WO (1) WO2012099983A1 (es)
ZA (1) ZA201305129B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
WO2013173706A2 (en) 2012-05-18 2013-11-21 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
WO2014151472A1 (en) 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
FR3007656B1 (fr) * 2013-06-28 2015-06-26 Galderma Res & Dev Modulateurs du canal sodique nav1.9 pour le traitement d'une maladie cutanee inflammatoire et methodes diagnostiques
FR3007763A1 (fr) * 2013-06-28 2015-01-02 Galderma Res & Dev Anticorps diriges contre le canal sodique nav1.9 humain et leurs utilisations en diagnostic
FR3007762B1 (fr) * 2013-06-28 2015-09-04 Galderma Res & Dev Anticorps diriges contre le canal sodique nav1.9 humain et leurs utilisations pour le diagnostic des maladies cutanees inflammatoires
RU2016113156A (ru) 2013-09-10 2017-10-16 Хромоселл Корпорейшн Модуляторы натриевого канала для лечения боли и диабета
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
KR20160064192A (ko) 2013-10-03 2016-06-07 얀센 바이오테크 인코포레이티드 프로톡신-ii 변이체 및 사용 방법
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP2918166A1 (en) 2014-03-10 2015-09-16 Westfälische Wilhelms-Universität Münster TTP/MRP14 double knock out mouse model of psoriasis
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
MX2017012654A (es) 2015-04-02 2018-01-09 Janssen Biotech Inc Variantes de protoxina-ii y metodos de uso.
CN105684993B (zh) * 2016-02-01 2018-06-01 江苏大学 GABAergic神经元条件性敲除基因PGC-1α小鼠的制备
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN111560076B (zh) * 2020-05-15 2021-05-07 广州百暨基因科技有限公司 一种嵌合抗原受体免疫细胞及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
HU213571B (en) 1988-07-23 1997-08-28 Delta Biotechnology Ltd Process for producing peptides and dna sequences
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2128862C (en) 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DK0942968T3 (da) 1996-12-03 2008-06-23 Amgen Fremont Inc Fuldt humane antistoffer, der binder EGFR
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
WO2000031284A1 (fr) 1998-11-20 2000-06-02 Fuso Pharmaceutical Industries, Ltd. Vecteur d'expression de proteine et utilisation de ce dernier
AU4010400A (en) 1999-03-18 2000-10-04 Human Genome Sciences, Inc. 27 human secreted proteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
JP4808156B2 (ja) 2003-08-05 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
GB0512214D0 (en) * 2005-06-15 2005-07-27 Capsant Neurotechnologies Ltd Method
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
RS53941B1 (en) 2009-01-12 2015-08-31 Pfizer Limited SULFONAMID DERIVATIVES

Also Published As

Publication number Publication date
MX2013008282A (es) 2014-02-10
JP2014507136A (ja) 2014-03-27
ZA201305129B (en) 2014-08-27
AU2012207366A1 (en) 2013-07-11
CN103492575A (zh) 2014-01-01
WO2012099983A1 (en) 2012-07-26
US20120185956A1 (en) 2012-07-19
CA2823707A1 (en) 2012-07-26
SG191993A1 (en) 2013-08-30
EP2665822A1 (en) 2013-11-27
EA201370161A1 (ru) 2013-12-30
KR20140009311A (ko) 2014-01-22

Similar Documents

Publication Publication Date Title
CL2013002068A1 (es) Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
BR112016028285A2 (pt) métodos para colheita de culturas de células de mamíferos
DK3013964T3 (da) Sammensætninger til indføring af rna i celler
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
DK3351620T3 (da) Metabolsk optimeret cellekultur
DK3242903T3 (da) Sammensætninger til at indføre nukleinsyre i celler
DK2889993T3 (da) Energilagringssystem til vedvarende energikilde
BR112013028289A2 (pt) sistemas solares híbridos e métodos de produção
DK3253863T3 (da) Bioreaktorsystem til celledyrkning
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
FR3008422B1 (fr) Procede de culture cellulaire decouple
CL2016001147A1 (es) Anticuerpos específicos para fcrn.
BR112016009753A2 (pt) método de cultura de células.
UY34335A (es) ?dispositivos, sistemas, y métodos para procesar materiales heterogéneos?.
BR112017020690A2 (pt) produção livre de células de ácido ribonucleico
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
DK2825633T3 (da) Fremgangsmåde til dyrkning af E. coli-celler til høj densitet
CL2013001621A1 (es) Molecula de acido nucleico reguladora con especificidad definida, construccion de expresion que la comprende, vector; microorganismo, celula vegetal o animal; y metodo para la produccion de dicha molecula.
DK3766582T3 (da) Cellekultur
DK3516038T3 (da) Anaerobt biogasanlæg
DE102016111219A8 (de) Brennstoffzellensystem
DK3336268T3 (da) Tætningskobling til rør, såsom til udløbsrør
EP3488482A4 (en) INTERMEDIATE TEMPERATURE FUEL CELL SUITABLE FOR EFFICIENT USE OF METHANE
DE112014006603A5 (de) Biomoleküle freisetzende Zelle und deren Selektion mittels eines Oberflächenproteins sowie für dieses codierende Nukleinsäure, deren Expressionsvektor und dessen Empfängerzelle